symposium - ean.org...this symposium will address the most frequent causes of movement disorders...

Symposium (ID: SYMP01) Innovative treatment approaches of inherited neuromuscular disorders

Saturday, 23 May 2020

10:00:00 AM - 12:00:00 PM

Main Auditorium

Chairpersons: Maria Judit Molnar, Budapest, Hungary (ID: 62173)

Teresinha Evangelista, Paris France

Gene therapeutic approaches of neuromuscular disorders (ID: SYMP01_1)

Teresinha Evangelista, Paris, France (ID: 34168)

The evolving landscape of RNA-based therapies (ID: SYMP01_2)

Giuseppe Vita, Messina, Italy (ID: 15217)

Towards a better understanding of enzyme replacement therapies (ID: SYMP01_3)

Mark Roberts, Manchester, United Kingdom (ID: 16842)

The role of small molecule approaches treating inherited neuromuscular disorders (ID:

SYMP01_4)

Maria Judit Molnar, Budapest, Hungary (ID: 62173)

Scientific/Educational Content:

Recent advances in understanding pathophysiological and genetic mechanisms of some

neuromuscular diseases and a rapid progress in new pharmacological technologies led to an

accelerated development of innovative treatments, generating an unexpected therapeutic revolution.

The symposia will focus on already commercially available drugs, just approved drugs and new

therapeutic promises in the treatment of inherited neuromuscular disorders. The lectures will cover

the topics of gene therapy, RNA based treatments, enzyme replacement therapies and innovative

small molecule approaches (new chemical entities and repositioned drugs) as well.

(ID: SYMP02) EAN/MDS-ES: Movement disorders in the emergency room


10:00:00 AM - 12:00:00 PM

Room Oslo

Chairpersons: Timothy Lynch, Dublin, Ireland (ID: 7109)

Movement disorders in congenital and acquired metabolic diseases (ID: SYMP02_1)

Miryam Carecchio, Padua, Italy (ID: 44445)

How to recognize an acute functional movement disorder (ID: SYMP02_2)

Jon Stone, Edinburgh, United Kingdom

Movement disorders in autoimmune encephalitides (ID: SYMP02_3)

Maria Stamelou, Athens, Greece (ID: 28934)

Drug-induced movement disorders (ID: SYMP02_4)

Timothy Lynch, Dublin, Ireland (ID: 7109)


Patients presenting with acute or subacute movement disorders are frequently encountered in routine

clinical practice. The number of possible causes of an acute movement disorders is wide, and

neurologists must be able to rapidly perform a case-based differential diagnosis.

This symposium will address the most frequent causes of movement disorders with an acute

presentation including treatable conditions not to miss.

(ID: SYMP03) EAN/IFCN-EMEAC: Neurophysiology and non-invasive brain stimulation

(NIBS)


10:00:00 AM - 12:00:00 PM

Room Vienna

Chairpersons: Walter Paulus, Göttingen, Germany (ID: 3550)

Hatice Tankisi, Aarhus, Denmark

Entrainment of brain function: bridging transcranial electric and magnetic stimulation (ID:

SYMP03_1)

Walter Paulus, Göttingen, Germany (ID: 3550)

NIBS in neuropathic pain syndromes (ID: SYMP03_2)

Jean Pascal Lefaucheur, Créteil, France (ID: 6247)

Brain-state-dependent NIBS: a new era for treating disordered brain networks (ID:

SYMP03_3)

Ulf Ziemann, Tubingen, Germany (ID: 56982)

The safety of NIBS and its uses in neuropsychiatry (ID: SYMP03_4)

Simone Rossi, Siena, Italy (ID: 99567)


This gives four lectures which will de-mystify an emerging and complex field. The lectures will give

reviews of the use of NIBS in specific neurological diseases as well as consider its safety and effects on

underlying brain function. We aim to show clinical neurophysiological techniques can be therapeutic

as well as diagnostic, and to give delegates more confidence about knowing the optimal uses of NIBS.

(ID: SYMP04) Promoting structural repair and functional recovery in multiple sclerosis


10:00:00 AM - 12:00:00 PM

Room Copenhagen

Chairpersons: Hans-Peter Hartung, Dusseldorf, Germany (ID: 3360) Catherine Lubetzki, Paris, France (ID: 6833)

Pathophysiological basis of functional recovery (ID: SYMP04_1)

Diego Centonze, Rome, Italy (ID: 99568)

Imaging methods to evaluate remyelination and neuroprotection (ID: SYMP04_2)

Benedetta Bodini, Paris, France (ID: 75633)

Ongoing and future therapeutic strategies (ID: SYMP04_3)

Hans-Peter Hartung, Dusseldorf, Germany (ID: 3360)

Stem cells therapy (ID: SYMP04_4)

Gianvito Martino, Milan, Italy (ID: 14334)


Promoting central nervous system remyelination and neuroprotection is crucially needed to prevent

disability progression in multiple sclerosis. This session will review the very recent discoveries that

decipher the mechanisms of myelin repair and neuroprotection, as well as the functional

consequences of the repair process. The latest developments of translational studies focusing on repair

will be reported, with a focus on the development of screening tools to identify pro-remyelinating or

neuroprotective molecules/pathways, and the analysis of completed and ongoing endogenous and

exogenous (stem cells) repair strategies. How these repair strategies will benefit from innovative study

designs will also be addressed.

(ID: SYMP05) EAN/ESO: Update on acute stroke treatment

Monday, 25 May 2020

3:00:00 PM - 5:00:00 PM

Main Auditorium

Chairpersons: Valeria Caso, Perugia, Italy (ID: 24320) Laurent Puy, Lille, France (ID: 99588)

Intravenous thrombolysis: Evidence for on- and off-label treatment (ID: SYMP05_1)

Else Sandset, Oslo, Norway

Endovascular stroke treatment beyond guidelines (ID: SYMP05_2)

Marc Ribo, Barcelona, Spain,

ICH management: the targets beyond hematoma expansion (ID: SYMP05_3)

Laurent Puy, Lille, France (ID: 99588)

Restarting antithrombotic agents after stroke and ICH (ID: SYMP05_4)

Valeria Caso, Perugia, Italy (ID: 24320)

(ID: SYMP06) EAN/EFAS: Highlights in the expanding arena of autonomic disorders

Monday, 25 May 2020

3:00:00 PM - 5:00:00 PM

Room Vienna

Chairpersons: Gregor K. Wenning, Innsbruck, Austria (ID: 7517)

Disease modification in multisystem atrophy (MSA): what's in the pipeline? (ID: SYMP06_1)

Gregor K. Wenning, Innsbruck, Austria (ID: 7517)

Ictal autonomic changes to predict and prevent SUDEP (ID: SYMP06_2)

Roland Thijs, Hemsteede, The Netherlands (ID: 24056)

Clinical implications of autonomic nervous system dysfunction in multiple sclerosis (ID:

SYMP06_3)

Mario Habek, Zagreb, Croatia (ID: 22559)

Relevance of autonomic space medicine for daily clinical neurology (ID: SYMP06_4)

Jens Jordan, Cologne, Germany (ID: 99569)


G. Wenning will cover: Pathogenic targets: oligodendroglial alpha synuclein and beyond; Early

diagnosis: role of autonomic, imaging and wet biomarkers; Neuroprotective candidates in the pipeline.

R. Thijs will cover: Seizures can alter autonomic function, particularly if the central autonomic network

is involved; Autonomic alterations may provide an adequate tool for early seizure detection and

facilitate timely interventions; Postictal arrhythmias and apneas may lead to SUDEP, which usually

occurs several minutes after a convulsive seizure; Raising an alarm at seizure onset may be sufficient

to allow timely intervention. M. Habek will talk about: A distinctive pattern of ANS dysfunction exists

in MS: the disease activity, which is more prevalent in CIS and early RRMS, is associated with

sympathetic nervous system dysfunction, parasympathetic nervous system dysfunction becomes more

evident with the progression of the disease. On a molecular level, changes in expression of different

receptors responsible for the communication between ANS and immune systems may modulate

inflammatory response and thus have an influence on MS disease activity or progression. Damage of

the brainstem and spinal cord due to MS may contribute to the development of ANS dysfunction. But

on the on the other hand ANS dysfunction can predict development of disease activity in MS. As ANS

dysfunction in early MS mainly driven by the sympathetic nervous system abnormalities, this may

explain increased risk of cardiovascular disease after MS onset. J. Jordan will cover: Launch into space

triggers highly significant, coherent haemodynamic and autonomic changes. Space travel alters human

haemodynamic and autonomic function at rest, during routine activities and during different

interventions. Studies investigating changes of ANS in astronauts are giving us unique new perspective

on long‐term human autonomic neuroplasticity.

(ID: SYMP07) Epilepsy – what to do with a pharmacoresistant patient?

Tuesday, 26 May 2020

8:00:00 AM - 10:00:00 AM

Main Auditorium

Chairpersons: Ivan Rektor, Brno, Czech Republic (ID: 8626)

Margitta Seeck, Geneva, Switzerland

Antiepileptic drug treatment for refractory epilepsy: the who, when, and how. (ID:

SYMP07_1)

Sylvain Rheims, Lyon, France (ID: 50016)

Epilepsy surgery: the who, when, and how (ID: SYMP07_2)

Kristina Malmgren, Mölndal, Sweden (ID: 8224)

Neurostimulation: the who, when, and how. (ID: SYMP07_3)

Ivan Rektor, Brno, Czech Republic (ID: 8626)

On-demand treatment of seizures (ID: SYMP07_4)

Andreas Schulze-Bonhage, Freiburg, Germany (ID: 630)


In more than 25% of persons with epilepsy the seizure freedom cannot be achieved with usual drug

treatment. There are millions of drug-resistant patients with epilepsy in Europe, but only a small

proportion are referred to tertiary centres that can offer the full range of treatment options. The

purpose of this session is to inform the general neurological audience about all possibilities of further

treatment of pharmacoresistant patients i.e. advanced pharmacotherapy, indications and contra-

indications of surgical treatment including palliative and neurostimulation methods.

(ID: SYMP08) Non-Alzheimer pathology in the elderly: what to do? Tuesday, 26 May 2020

8:00:00 AM - 10:00:00 AM

Room Vienna

Chairpersons: Flavio M. Nobili, Genoa, Italy (ID: 34837)

Philip Scheltens, Amsterdam, The Netherlands (ID: 11462)

The concept of Suspected non-Alzheimer disease pathophysiology (SNAP) in 2020: does it

still survive? (ID: SYMP08_1)

Philip Scheltens, Amsterdam, The Netherlands (ID: 11462)

Primary age-related tauopathy: are we able to intercept it? (ID: SYMP08_2)

Irina Alafuzoff, Uppsala, Sweden (ID: 99570)

Limbic-predominant age-related TDP-43 encephalopathy (ID: SYMP08_3)

Gabor Kovacs, Toronto, Canada (ID: 21678)

Cerebral amyloid angiopathy (ID: SYMP08_4)

Dietmar Thal, Leuven, Belgium (ID: 99571)


Emerging topics in primary CNS pathologies leading to cognitive deterioration include a variety of still

partially known conditions that can coexist to various extents with Alzheimer pathology. These are

challenging conditions because the availability of biomarkers as well as clinical profiling are still poor.

However, as a whole these pathologies account for about twenty percent of the naturalistic population

presenting to a memory clinic because of cognitive complaints. They mainly affect the elderly

population and represent an issue in differential diagnosis with the classic and better-known

neurodegenerative diseases, ranging from AD to frontotemporal dementia. Moreover, they might

have been one among the causes leading to unsuccessful clinical trials with disease-modifying drugs in

AD. There is an urgent need to deepen our pathological and clinical knowledge in order to plan

diagnostic investigations and treatments, if any, otherwise in clinical practice they are highly likely to

remain under- or misdiagnosed. Both CSF and imaging biomarkers are still rather immature and thus

there is need of implementation of new diagnostic probes and case-studies with pathological

confirmation. The workshop brings together three among the most involved European scientists in the

field and is aimed to give a theoretical framework as well as practical guidance on how to manage

these patients with cognitive impairment but not classified in one of the better-known

neurodegenerative conditions.

(SYMP09) EAN/EHF: Unmet needs in acute treatment of migraine Sunday, 24 May 2020

15:00:00 PM - 16:30:00 PM

Room Amsterdam

Chairpersons: Christian Lampl, Linz, Austria

Acute migraine treatment in the emergency room

Anish, Bahra, London, United Kingdom

The triptans: history, potential, limitations

Stefan Evers, Muenster, Germany

Future drugs in acute migraine treatment

Christian Lampl, Linz, Austria

Specific needs during lifetime - childhood, pregnancy, old age

Aynur Özge, Mersin, Turkey

Focused Workshop (ID: FW01) Molecular mechanisms for the treatment of hereditary CNS disorders Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Main Auditorium

Chairpersons: Alexandra Dürr, Paris, France (ID: 6724))

Antisense oligonucleotides (ID: FW01_01)

Alexandra Dürr, Paris, France (ID: 6724)

CRISP-Cas9 (ID: FW01_02)

Alessandro Quattrone, Trento, Italy (ID: 99589)

Gene therapy (ID: FW01_03)

Hélène Puccio, Strasbourg, France (ID: 99590)


Treatment of genetic disorders is no more a dream. Antisense oligonucleotides, RNA-based therapies,

gene therapy are successfully applied in human genetic disorders. Crispr-Cas9 is very promising.

(ID: FW02) Overarching theme - Can we protect and repair the brain after stroke? Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Vienna

Chairpersons: Andrew Demchuk, Calgary, Canada (ID: 99591)

Renaissance of neuroprotection in the era of recanalization (ID: FW02_01)

Andrew Demchuk, Calgary, Canada (ID: 99591)

Will there ever be a mechanism to repair the brain after stroke? (ID: FW02_02)

Keith Muir

How can we protect the brain from secondary brain damage after ICH? (ID: FW02_03)

Urs Fischer, Bern, Switzerland


Mechanical thrombectomy revolutionized acute stroke treatment, but clinical outcomes are often still

unsatisfactory. After successful recanalization leading to transient brain ischemia neuroprotective

measures which failed during permanent ischemia in clinical trials may witness a revival and rescue

neurons. Given the large number of patients which cannot receive recanalization treatment there is

an urgent demand to foster repair by modulating reorganisation of the brain. Finally, after ICH there is

increasing brain damage by secondary processes such as edema formation. This workshop will address

recent achievement in our understanding of these processes which have an immense impact on

patient´s wellbeing.

(ID: FW03) EAN/MDS-ES: Axial Symptoms and Cognition in Parkinson's Disease Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Lisbon

Chairpersons: Caroline Moreau, Lille, France (ID: 56616)

Relationship between axial symptoms and cognition in Parkinson's Disease (ID: FW03_1)

Miguel Coelho, Lisbon, Portugal (ID: 83019)

Speech, swallowing and gait impairment as disability milestones in PD (ID: FW03_2)

Caroline Moreau, Lille, France (ID: 56616)

New therapeutic concepts for axial disorders in PD (ID: FW03_3)

Anat Mirelman, Tel Aviv, Israel (ID: 99572)


Axial disorders, namely speech and gait disturbances, are among the most disabling symptoms of

Parkinson’s disease, and are still handled in an unsatisfactory manner. Also recognized is the

association between different disability milestones like cognitive impairment, swallowing problems,

speech impairment and gait and freezing problems. In this focused workshop, axial symptoms in PD

will be presented and its relationship with cognitive impairment. It will be presented the advances in

the understanding of the multifactorial origins of gait changes in patients with Parkinson’s disease

promoted the development of new intervention strategies, such as neurostimulation and virtual

reality, aimed at alleviating gait impairments and enhancing functional mobility. This session is

supported by the speech impairment study group of the Movement Disorder society group.

(ID: FW04) EAN/EFAS: Autonomic nervous system and digestive tract: NEW Insights Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Copenhagen

Chairpersons: Max J. Hilz, Erlangen, Germany (ID: 3334)

Role of the vagus nerve on sensibility, motricity and digestive inflammation (ID: FW04_1)

Bruno Bonaz, Grenoble, France (ID: 92267)

Enteric nervous system in neurodegenerative disorders of the CNS (ID: FW04_2)

Pascal Derkinderen, Nantes, France (ID: 5869)

Gastrointestinal dysfunction in genetic treatable autonomic disorders: Fabry disease, Acute

Intermittent Porphyria, TTR-Familial Amyloid Polyneuropathy (ID: FW04_3)

Alessandro Burlina, Bassano del Grappa, Italy (ID: 32812)


Gastrointestinal dysfunction and complaints are very frequent but often not always well understood

by neurologists although GI problems are frequent signs and complications of autonomic diseases and

neurological diseases in general. After having attended this symposium, the participants will have a

better understanding of the role of the autonomic nervous system in common diseases such as

inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). They will better understand the

pathophysiology of gastric motility disorders and their treatment. They will have advanced their

knowledge regarding the role of the GI tract in neurodegenerative diseases such as Parkinson disease.

They will better differentiate various rare neurological diseases such as Hereditary Sensory and

Autonomic Neuropathy Type III, Fabry disease, TTR-FAP, acute intermittent porphyria.

The symposium attempts to close a gap in interest and understanding of common and thus clinically

relevant symptoms that are often referred to Gastroenterologists although they are in the domain of

neurology.

This symposium will review the role of the enteric nervous system (intrinsic nervous system of the GI

tract), and of the extrinsic autonomic nervous system in gastro-intestinal disorders, as well as the

complex interactions between gut and brain denominated the “gut brain-axis”. There is growing

evidence supporting the existence of these interactions and of their pathophysiological consequences.

(ID: FW05) Understanding apraxia Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Berlin

Chairpersons: Cornelius Weiller, Freiburg, Germany

Duality of Function: communication and manipulation (ID: FW05_1)

Prof Ferdinand Binkofski, Aachen, Germany

Duality of social function: Panto-mime and gestural expression (ID: FW05_2)

Angela Bartolo, Lille, France (ID: 99575)

Duality of Hodology: Apraxias - from anatomy to learning tool use to predicting effects of

rehabilitation (ID: FW05_3)

Cornelius Weiller, Freiburg, Germany (ID: 2244)


Apraxia is a common disorder, observed in patients with both focal lesions and neurodegenerative

conditions, which is often poorly assessed in clinical examinations. More than 100 years of research

and clinical experience has led to agreement that apraxia is not a unitary disorder. Instead, it consists

of many different types of functional disturbance which can be associated with lesions in several

different brain regions. However, it remains controversial how different functional deficits might map

to brain structures and processes. Emerging theories of apraxia propose that the diversity of

manifestations can be reduced to two basic functional dualities that are correlated with two

anatomical dualities. While a classical theory assigned “ideational” and “ideo-motor” phases of motor

planning to consecutive processing in posterior and anterior brain regions respectively, the validity of

this proposal has been cast into doubt by modern neuroimaging studies in large patient samples. New

theories of apraxia are instead based on a distinction between dorsal and ventral processing streams,

from posterior brain regions to anterior ones, separated by the Sylvian fissure. This workshop will

present recent progress in understanding the functional anatomy of apraxia with a particular emphasis

on implications for understanding normal mechanisms underlying praxis and motor control, and

clinical examination of apraxia for practising neurologists.

(ID: FW06) EAN/EANM: Neuroimaging in dementia: what are the news and what is the perspective? Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Budapest

Chairpersons: Massimo Filippi, Milan, Italy (ID: 14891)

Flavio M. Nobili, Genoa, Italy (ID: 34837)

MRI tools in cognitive disorders: what is consolidated and what is new? (ID: FW06_1)

Massimo Filippi, Milan, Italy (ID: 14891)

Impact of amyloid and Tau PET in diagnosis and prognosis of neurodegenerative diseases (ID:

FW06_2)

Alexander Drzezga, Cologne, Germany (ID: 99592)

Discordant PET and CSF biomarkers: what can we learn? (ID: FW06_3)

Femke H. Bouwman, Amsterdam, The Netherlands (ID: 39135)


Clinical diagnosis of diseases causing cognitive impairment is increasingly based on biomarkers.

Neuroimaging biomarkers, both structural and functional, are in a key position but both evidence and

clinical maturity are still partly incomplete. New tools are in the pipeline based on the two key

modalities, i.e. MRI and PET. Morphological MRI has gained a main position in the diagnosis and

severity definition of Alzheimer disease (AD), frontotemporal lobe degeneration (FTLD) in its several

clinical presentations, Jacob-Creutzfeldt disease, and vascular cognitive impairment. Diffusion-tensor

imaging has clarified how white matter tracts are involved in neurodegeneration. fMRI has added and

impressive bulk of data to pathophysiological mechanisms of dementing disorders but clinical utility is

still limited. New techniques, such as arterial spin labelling (ASL) to measure CBF, are very promising

but still in progress. On the other hand, while FDG-PET has gained a pivotal position in the diagnosis of

the majority of neurodegenerative conditions, including AD, FTLD, and dementia with Lewy bodies

(DLB), amyloid PET is the only method to visualize amyloid load in the brain in patients with AD and in

a part of asymptomatic elderly population whereas a negative scan virtually exclude an AD diagnosis.

Tau-protein radiopharmaceuticals are in advanced stage of development and it is likely they will be on

the market soon while in perspective new tracers to image inflammation, both at the microglia and

astrocyte level, and synaptic function could shed light in the pathophysiology of neurodegenerative

diseases.

(ID: FW07) Neuronal ceroid lipofuscinosis (NCL): focus on innovative treatments Saturday, 23 May 2020 8:00:00 AM - 9:30:00 AM

Room Paris

Chairpersons: Alessandro Simonati, Verona, Italy (ID: 14915)

Neuronal Ceroid Lipofuscinosis: an update (ID: FW07_1)

Alessandro Simonati, Verona, Italy (ID: 14915)

NCL of Childhood onset: innovative treatment, care and management (ID: FW07_2)

Angela Schulz, Hamburg, Germany (ID: 99573)

NCL of Adulthood onset: what we know and we should learn about diagnosis and treatment

(ID: FW07_3)

Filippo Santorelli, Pisa, Italy (ID: 99574)


The Neuronal Ceroid Lipofuscinosis (NCL) are a heterogenous group of inherited, progressive

encephalopathies mostly of childhood; a small group of adult onset NCL are also known. They are

named after the distinctive pathological features of the presence of autofluorescent, endolysosomal

storage material with different ultrastructural patterns and ceroid accumulation and are considered

as Lysosomal Storage Disease. NCL are grouped according to the age of onset into 4 subgroups:

infantile, late infantile, juvenile and adult forms, and the mutated gene. So far 13 genes have been

identified whose alterations are associated with great phenotypic heterogeneity. Untreatable epilepsy

with myoclonus, progressive decline of cognitive and motor functions, ataxia, and loss of vision to

blindness are the clinical hallmarks shared among the different forms. Actually, only 4 subtypes are

associated with impaired enzymatic activity of a lysosomal hydrolase; endolysosomal storage seems

to occur due to other mechanisms, affecting the lysosomal compartment, including malfunctioning

autophagy. To date, NCL remain fatal diseases with the length of survival being related to the severity

of the form. No curative treatments are available. However, over last few years innovative treatments

were developed as Replacement Therapies (RT) for childhood onset NCL: one of them is already

available on the market, and phase I/II clinical trials are expected shortly for other forms. Aim of this

workshop is to review the actual knowledge and definition of NCL, describe the state-of-art of available

treatments in childhood NCL, discuss the diagnostic difficulties of adult onset NCL, and comment the

potential changes in care and management due to the development of new drugs and gene therapy

opportunities.

(ID: FW08) Prediction, prevention and personalised treatment approaches of neuromuscular disorders Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Vienna

Chairpersons: Corrado Angelini, Venice, Italy (ID: 14145)

Personalized treatment approaches of neuromuscular disorders (ID: FW08_1)

Jan de Bleecker, Ghent, Belgium (ID: 9639)

Biomarkers of disease progression and treatment efficacy (ID: FW08_2)

Philip Van Damme, Leuven, Belgium (ID: 40827)

Newborn screening in neuromuscular disorders (ID: FW08_3)

Corrado Angelini, Venice, Italy (ID: 14145)


The future direction in the healthcare is the precision medicine which is focusing on prevention,

prediction and personalized treatment approaches of the disorders. In the neurology it is in the most

advanced phase in the neuromuscular disorders, since in some forms of these disorders mutation

specific treatment options, early prediction and prevention is available. The newborn screening offers

a new option for presymptomatic treatments but at the same time raises some ethical questions as

well. The focused workshop will present the newest research data and discuss its implementation in

the everyday clinical practice.

(ID: FW09) EAN / AAN: Predict, prevent and repair in CNS tumors

Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Lisbon

Chairpersons: Stefan Oberndorfer, St. Pölten, Austria (ID: 19648)

Scott Plotkin, Boston, USA (ID: 99580)

IDH mutations as predictive factors and potential target of therapy in gliomas (ID: FW09_1)

Michael Platten, Heidelberg, Germany (ID: 4893)

How to prevent radiation-induced cognitive damage in brain metastasis: hippocampus

sparing or neuro-protective drugs or both? (ID: FW09_2)

Julian Jacob, Paris, France

Genetic alterations as predictive factors of phenotype and tumor development in

neurofibromatosis type 1 and 2 (ID: FW09_3)

Scott Plotkin, Boston, USA (ID: 99580)


The audience will be updated on recent advances regarding molecular factors of prognostic/predictive

importance in gliomas and neurofibromatosis, mechanisms of repair of damage to the brain tissue

from antitumor treatments and strategies to minimize neurotoxicity.

(ID: FW10) Large scale brain networks as a readout of cognitive changes and treatment manipulations in Parkinson’s disease Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Amsterdam

Chairpersons: Irena Rektorova, Brno, Czech Republic (ID: 25305)

Large scale brain networks as a readout of cognitive changes and treatment manipulation in

PD (ID: FW10_1)

Irena Rektorova, Brno, Czech Republic (ID: 25305)

Neural correlates of modulation of cognitive symptoms by non-invasive approaches (ID:

FW10_2)

Jaime Kulisevsky, Barcelona, Spain (ID: 24313)

Deep brain stimulation and cognition (ID: FW10_3)

Fiorella Contarino, Leiden, The Netherlands (ID: 22136)


Cognitive impairment (CI) in PD is associated with a decrease of functional distinction between specific

brain areas that seems to occur on the level of resting-state functional brain networks, particularly

within the frontoparietal control network, cingulo-opercular (salience) network, and the default mode

network. Based on the theory of dedifferentiation, increases of inter-network cross-talk may serve

compensatory mechanisms in order to keep the global efficiency int act. We will focus on both

pharmacological and non-pharmacological treatments in PD-CI and provide insight from the network-

based perspective on how these interventions modulate brain function.

(ID: FW11) Overarching theme – EAN/ ILAE: Time is brain in epilepsy management Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Berlin

Chairpersons: Eugen Trinka, Salzburg, Austria (ID: 7765)

Rima Nabbout, Paris, France (ID: 65856)

Status epilepticus: time critical management (ID: FW11_1)

Eugen Trinka, Salzburg, Austria (ID: 7765)

Epilepsy: Impact of diagnostic and treatment delay (ID: FW11_2)

Rima Nabbout, Paris, France (ID: 65856)

Auto-immune epilepsy: delay, diagnosis and treatment challenges (ID: FW11_3)

Sarosh Irani, Oxford, United Kingdom (ID: 33500)


This workshop is highly relevant to all neurologists that see people with epilepsy and seizures.

1. Failure to recognise and appropriately manage status epilepticus can result in mortality

and significant morbidity. Recent guidelines and randomized controlled trials in adults

and in children inform treatment policies

2. Delay in diagnosing and managing epilepsy comes at significant cost to individuals and

society, yet most European centres fail to do get this right for their local population. We

must do better

3. Diagnosing and managing auto-immune encephalitis can be challenging, but due to lack

of randomised trials there is uncertainty as to the best treatment paradigms. Yet failure

to act comes at a cost.

(ID: FW12) Vector-borne neuro-infections Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Budapest

Chairpersons: Bettina Pfausler, Innsbruck, Austria (ID: 7844)

The European perspective (ID: FW12_1)

Pille Taba, Tartu, Estonia (ID: 18480)

The Asian perspective (ID: FW12_2)

Uta Meyding-Lamade, Frankfurt, Germany (ID: 1513)

The African perspective (ID: FW12_3)

Erich Schmutzhard, Innsbruck, Austria (ID: 7155)


Over the past decades the world’s population has achieved a mobility of unimaginable dimensions. In

2018 more than 70 million migrants have left their home-country fleeing from life-threatening

conditions and/or looking for conditions to live a sufficiently safe and secure life. In the same year

more than 1.35 billion tourists, businesspeople and/or military personnel, NGO-workers and many

more have travelled by plane or ship transnationally and trans-continentally.

This “ultra-rapid mobility”, the changing climatic conditions allowing vectors to establish their life-

cycles in so far unknown environments and, then, to pick up “exotic” viruses from migratory animals

(esp. birds), all these facts, are the basis that diseases, so far unknown to the European neurologic

community, may lead to even life-threatening diseases (vector-borne neuro-infections being the most

frequent and “frightening” ones), in which earliest possible diagnoses and therapies are essential.

(ID: FW13) Fluid and structural disease biomarkers to predict neurodegenerative diseases Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Paris

Chairpersons: Mathias Jucker, Tubingen, Germany (ID: 447)

Fluid Biomarkers in models of neurodegenerative diseases: Bridging the translational gap (ID:

FW13_1)

Mathias Jucker, Tubingen, Germany (ID: 447)

CSF and blood-based disease and treatment response biomarkers in Alzheimer's diseases and

other neurodegenerative disorders (ID: FW13_2)

Charlotte E. Teunissen, Amsterdam, The Netherlands (ID: 29446)

Structural and functional markers of neurodegeneration: pre-clinical and clinical stages (ID:

FW13_3)

Frederica Agosta, Milan, Italy (ID: 30604)


This workshop will highlight the benefits of integrated translational and clinical research and present

a series of biomarkers that will contribute to predict disease onset and allow preventive therapeutical

interventions. We specifically aim at bridging animal model based clinically relevant biomarker findings

to clinical research in neurodegenerative diseases with particular emphasis on preclinical Alzheimer´s

disease (AD). AD abnormalities in brain occur at least 10–20 years before the onset of the first

symptoms in both sporadic and familial AD. This early stage has been termed “preclinical AD”, and is

an important focus of research as it is considered the most promising period for successful disease-

modifying therapies and prevent disease progression. Disease-specific biomarkers constitute a

reasonable approach to define preclinical AD and predict which individuals will become symptomatic.

The earliest biomarkers for characterizing patients are low levels of Aβ42 and high levels of Tau protein

in cerebrospinal fluid (CSF). The first speaker will address CSF Aβ, Tau and Neurofilament Light Chain

changes in APP tg mice that are virtually identical to what is predicted to occur in AD patients. The CSF

total (t)-Tau increase in APP tg mice occurs in the absence of neurofibrillary tangles and overt neuron

loss and strongly correlates with Aβ pathology in brain and, in preclinical models, CSF t-Tau constitutes

a useful endpoint for Aβ targeting therapies, particularly in pre-clinical AD stages. Plasma

Neurofilament Light Chain dynamic changes in models of different protheopatic neurodegenerative

diseases (Beta amyloid, A-synuclein and Tau transgenic mouse models) constitute a promising

biomarker to predict response to treatment or disease progression in animal models. Data from

Preclinical disease cohorts included in the Dominantly Inherited Alzheimer Network (DIAN) further

strengthen the translational potential of mouse models. Furthermore axonal, neuro-inflammatory and

glial biomarkers are being increasingly recognized as fluid biomarker candidates to increase diagnostic

sensitivity and specificity and allow for patient stratification for disease oriented treatments. The

second speaker will address fluid (CSF and blood) biomarker panels for diagnosis and to predict

response to treatments. Microglial, inflammatory and neurodegenerative biomarkers profiles in AD

will be explored and a multi-marker panel will be suggested for patient assessment and stratification.

CSF and blood NfL dynamics across different neurodegenerative diseases and the implications in the

differential diagnosis. (Parkinson´s disease and atypical parkinsonism, FTD, CJD and ALS). The value of

reliable quantification using fourth generation (single-molecule array) assay and longitudinal follow-

up of neuroaxonal damage are important for assessing disease activity, predicting treatment

responses, facilitating treatment development and determining prognosis. Findings from large LOAD

cohorts like ADNI or FAD like DIAN will be highly informative for future integrated approaches in AD

and in other neurodegenerative diseases as we are now on track to predict how individuals at risk will

progress towards clinical AD. Third speaker will address the current and future use of imaging

biomarkers (both functional and structural) in preclinical AD, predicting disease conversion and

management of AD patients. We will cover several methodological approaches like Positron-Emission-

Tomography (PET) including various tracers, as well as conventional and advanced Magnetic

Resonance Imaging (MRI) techniques including MR spectroscopy, diffusion tensor and magnetic

transfer imaging and functional MRI. Modern neuroimaging tools to identify distinct neural networks

(connectomics) will be combined with target-specific positron emission tomography (PET) to explore

connectome dysfunction and Aβ and Tau proteopathic spatiotemporal spreading in the AD brain. The

neuronal network and synaptic activities are beginning to change in preclinical AD, thus functional

connectivity analysis will be explored to detect subtle brain network abnormalities and predict the very

beginning of AD pathology in the brain. Overall, this workshop will thus provide integrative data for

neurologists to understand current status of fluid and imaging biomarkers in the diagnosis of AD and

other neurodegenerative diseases. Moreover, neurologists will learn which biomarkers can predict

disease progression and response to treatment (prevent). In addition, neurologists will have an

overview on future biomarker panels and the role of basic and clinical crosstalk in Biomarker research.

(ID: FW14) New insights into vascular cognitive impairment (VCI): from basic science to prevention and treatment Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Main Auditorium

Chairpersons: Hugh Markus, Cambridge, United Kingdom (ID: 16903)

New insights into VCI from basic science (ID: FW14_1)

Anne Joutel, Paris, France (ID: 99576)

Preventing VCI - recent advances (ID: FW14_2)

Reinhold Schmidt, Graz, Austria (ID: 7246)

Treating VCI - recent advances (ID: FW14_3)

Hugh Markus, Cambridge, United Kingdom (ID: 16903)


Vascular cognitive impairment, most often caused by cerebral small vessel disease, is the second most

common cause of dementia and is a major contributor to mixed dementias which accounts for the

majority of dementia cases in the elderly. Recent insights from basic science, particularly led by the

Paris group of Anne Joutel, together with information from genetics have highlighted novel processes

involved in the disease including a central role for disruption of the extracellular matrix in the small

vessel in the brain. These are suggesting new treatment options, some of which are being tested in

new trials. This focussed workshop will span VCI from recent basic science advances through to the

clinical arena and how these are translating into better strategies for prevention and treatment of

disease. It will be of interest both to clinicians wanting an update in this rapidly progressing and

clinically important field, and basic scientists who want to put their work into clinical context.

(ID: FW15) How is intracranial pressure regulated? Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Vienna

Chairpersons: Jan Hoffmann, London, United Kingdom (ID: 81684)

The molecular basis of CSF-production (ID: FW15_1)

Jan Hoffmann, London, United Kingdom (ID: 81684)

The role of glymphatics in CSF disorders (ID: FW15_2)

Martin K. Rasmussen, Copenhagen, Denmark (ID: 67746)

CSF dysregulation: consequences in the clinic (ID: FW15_3)

Susan Mollan, Birmingham, United Kingdom (ID: 99594)


The glymphatic system has recently been described as very important for headache and trigeminal

pain disorders. This includes the interaction of glia cells, CSF metabolism and intracranial pressure. This

symposium will update the participants on the recent scientific findings of the glymphatic system and

on their role in headache disorder, in particular intracranial pressure changes.

The headache disorders associated with changes in intracranial pressure will be presented and recent

treatment recommendations will be given.

(ID: FW16) Genetic testing in epilepsy in 2020: When to ask for it and how it can contribute

to epilepsy management Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Lisbon

Chairpersons: Guido Rubboli, Dianalund, Denmark (ID: 67038)

An overview of recent development in epilepsy genetics (ID: FW16_1)

Holger Lerche, Tubingen, Germany (ID: 4305)

To whom should we offer genetic testing in epilepsy? (ID: FW16_2)

Carla Marini, Florence, Italy (ID: 99577)

How can genetics contribute to the clinical management in epilepsy? (ID: FW16_3)

Guido Rubboli, Dianalund, Denmark (ID: 67038)


The last decade has witnessed the discovery of many genes involved in epilepsy. Most of these genes

are expressed in the brain and encode subunits of ion channels that play vital roles in stabilizing or

propagating neuronal activity. Disruption of these genes in general induces neuronal hyperexcitability,

thus causing seizures. There are many forms of epilepsies. A single gene may be associated with

different forms of epilepsy, but one type of epilepsy may also result from defects in any one of a variety

of genes.

The purposes of this Focus Workshop are:

1) to provide an overview of the most recent developments in epilepsy genetics

2) to provide some guidance on which groups of epilepsy patients might benefit from genetic

testing

3) to illustrate how genetic testing can help to clarify the diagnosis and to inform on the

prognosis, and how it can potentially orient treatment strategies and open new avenues of

treatment.

(ID: FW17) EAN / ECTRIMS: The emerging importance of "other cells" in multiple sclerosis Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Amsterdam

Chairpersons: Luca Massacesi, Florence, Italy (ID: 14201)

The astrocytes in MS (ID: FW17_1)

Sandra Amor, Amsterdam, The Netherlands (ID: 99596)

The microglia in MS (ID: FW17_2)

Sarah C. Starossom, Berlin, Germany (ID: 99595)

Antigen presenting cells in the CNS, perivascular cuffs and compartmentalization of the

immune response (ID: FW17_3)

Luca Massacesi, Florence, Italy (ID: 14201)

Scientific Content:

Understanding functions of the CNS cells and their interaction with the effector immune mechanism

in general as well as specifically in MS, is critical for understanding the disease and to explore the new

treatment alternatives that may arise. In the recent years experimental and clinical studies on different

CNS cells had shown that – beside the effector lymphocytes infiltrating from the periphery-, CNS

resident cells such as astrocytes, microglia and pericytes play major roles in the pathogenesis of MS. A

key issue related to the role of the resident cells in MS lesion development, is the fine mechanisms and

the actual sites where effector immune response against CNS interacts with the CNS antigens and how

and when the effector inflammatory cells, compartmentalizes in the CNS, through a complex interplay

between adaptive and innate immune responses. Immunological and imaging data collected in the last

years allow indeed to generate new models of the MS lesion development and evolution based on a

deeper comprehension the of early events occurring in the perivascular spaces at the sites of the small

venules where professional APC are present, and on the role of the BBB. New and reliable models of

the acute to chronic lesion conversion as well, is now also possible. In this focused workshop the role

of these cells and of these events in the neuroinflammation and neurodegeneration of MS and their

potential contribution in the management of the disease will be discussed.

(ID: FW18) Brain-Computer Interfaces (BCI): Communication and rehabilitation Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Copenhagen

Chairpersons: Surjo Soekadar, Berlin, Germany (ID: 99578)

Using BCI and exoskeletons for motor rehabilitation (ID: FW18_1)

Surjo Soekadar, Berlin, Germany (ID: 99578)

Benchmarking BCI outside the laboratory (ID: FW18_2)

Robert Riener, Zurich, Switzerland (ID: 99579)

BCI and other neurotechnology for the assessment & communication in disorders of

consciousness (ID: FW18_3)

Steven Laureys, Liege, Belgium (ID: 9620)

Scientific Content:

Brain Computer Interface (BCI) is an extremely important link between the brain, in particular

cognition, and the computer with all its analysis algorithms. The question whether the Computer can

‘read the mind’ is still an aim for the future but we are approaching it closer year by year with

improvements on both sides finding more and better transfers from brain to computer and developing

better electronic analysis technologies. The three speakers will present updates on the possibilities

and limitations of different BCI methods (mediated by EEG, NIRS or P300) and their use for arm motor

rehabilitation, for human-humanoid interaction and for communication with unresponsive patients.

BCI has increasing importance for Motor Rehabilitation and also for Communication even with

unresponsive patients.

This session was proposed and co-organised by the Scientific Panel on Higher cortical functions and

the Scientific Panel on Coma and disorders of consciousness.

(ID: FW19) EAN/ EANO: Emerging neurological complications in treatments of oncology Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Berlin

Chairpersons: Riccardo Soffietti, Torino, Italy (ID: 15072)

Neurological complications of Checkpoint Inhibitors (ID: FW19_1)

Andreas Hottinger, Lausanne, Switzerland (ID: 72694)

Neurological complications of Car-T-cell therapy (ID: FW19_2)

Antoine Carpentier, Paris, France (ID: 7035)

Neurological complications of targeted therapies and radiosurgery (ID: FW19_3)

Roberta Rudà, Turin, Italy

Scientific Content:

The audience will be updated on recent advances regarding molecular factors of prognostic/predictive

importance in gliomas and neurofibromatosis, mechanisms of repair of damage to the brain tissue

from antitumor treatments and strategies to minimize neurotoxicity

(ID: FW20) Fitness to drive in neurological disorders Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Paris

Chairpersons: David Schreier, Bern, Switzerland (ID: 67199)

Fitness to drive in sleepy patients (ID: FW20_1)

David Schreier, Bern, Switzerland (ID: 67199)

Fitness to drive in patients with cognitive impairments (ID: FW20_2)

Dorota Religa, Stockholm, Sweden (ID: 23643)

Fitness to drive in patients with epilepsy (ID: FW20_3)

Philip Smith, Cardiff, United Kingdom (ID: 92536)

Scientific Content:

In this Focused Workshop, we would like to inform regarding the latest research and their impact on

the judgement of fitness to drive. Due to many reasons, being able to drive is very important for

patients. However, the judgment of fitness to drive often remains challenging. The number of patients

with neurological disorders is increasing, while the opportunities for treatment and the availability and

quality of driving assistant systems are improving, enabling more severely disabled patients to carry

on driving. Therefore, not only the number but also complexity of decisions that need to be made by

physicians, particularly neurologists, has increased.

(ID: FW21) Clinical impact of white matter hyperintensities and microbleeds Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Copenhagen

Chairpersons: Stephanie Debette, Bordeaux, France (ID: 46210)

David Werring, London, United Kingdom (ID: 16495)

New molecular insights into cerebral small vessel disease (ID: FW21_1)

Martin Dichgans, Munich, Germany (ID: )

Epidemiology and genomics of cerebral small vessel disease: implications for treatment (ID:

FW21_2)

Stephanie Debette, Bordeaux, France (ID: 46210)

Diagnostic and therapeutic importance of microbleeds (ID: FW21_3)

David Werring, London, United Kingdom (ID: 16495)

Scientific Content:

Within the aging population the number of patients showing MRI abnormalities, in particular white

matter hyperintensities (WMH) and microbleeds increases. This workshop provides novel insights into

cerebral small vessel disease underlying WMH and their implication for treatment. A further important

clinical problem covered relates to balancing the risk of future intracranial bleeding compared to the

risk of recurrent ischemic stroke in patients with a high burden of microbleeds.

Special Session SPS13: COVID-19 Session EAN 2020

Sunday, 24 May 2020

15:00:00 AM - 16:30:00 PM

Main Auditorium

Chairpersons: Elena Moro

Tom Jenkins,

1. Ethical considerations during the COVID-19 Pandemic

2. Diagnosis and medical care of COVID-19

3. Neurological manifestations and outcome of SARS-CoV-2 infection

4. Virological and neurobiological view on SARS-CoV-2

Renaud Du Pasquier, Lausanne, Switzerland

(ID: SpS01) WHO Strategies in brain diseases: noncommunicable diseases and universal

healthcare coverage


8:00:00 AM - 9:30:00 AM

Room Seville

Chairpersons: William Carroll (WFN President)

Günther Deuschl, Kiel, Germany

Global, regional, and national burden of neurological disorders

Ettore Beghi, Italy

Stroke and dementia burden- opportunities for prevention

David Tanne, Haifa, Israel

Strategic Epilepsy Initiatives in the WHO

Alla Guekht, Moscow, Russia

4a) Migraine and tension-type headache in Europe- reducing the burden of disease

Timothy Steiner, London, United Kingdom

4b) WHO strategies in promoting brain health

WHO Representative (TBC)

Scientific Content:

As demonstrated by GBD study, the burden of neurological disorders, as measured by the absolute

number of DALYs, continues to increase. As populations are growing and ageing, the prevalence of

major disabling neurological disorders has been predicted to increase further.

Stroke remains one of the leading causes of death and disability in Europe. Stroke is more prevalent in the elderly, however, stroke in the young and middle-aged adults are increasingly frequent, likely because of metabolic risk factors, including obesity and diabetes mellitus. Recent advances in stroke treatment allowed to prevent severe disability and mortality is huge number of patients worldwide,

and there is a compelling evidence that stroke is highly preventable, treatable and manageable, and the potential exists to drastically reduce the burden of stroke and its long-term consequences. The medical rationale for stroke being a disease of the brain is overwhelming, and in the ICD-11 stroke will be appropriately placed in the section of diseases of the nervous system. Epilepsy is a chronic noncommunicable disease of the brain that affects people. Around 50 million people of all ages worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low- and middle-income countries. It is estimated that up to 70% of people living with epilepsy could live seizure- free if properly diagnosed and treated. The risk of premature death in people with epilepsy is up to three times higher than for the general population. There is a growing evidence that a substantial proportion of epilepsies in brain diseases is preventable. The methods of seizure prediction are being developed. In 2019 the first-ever Global Report on epilepsy had been published by the WHO, ILAE and IBE. The WHO is paying increasing attention to the burden of the preventable noncommunicable diseases (NCDs), including brain diseases, in the close collaboration with the WFN and other leading neurological organizations. Advancing toward providing universal access to comprehensive, quality, progressively expanded health services, should take into account the health needs of people, including those affected by brain diseases and other NCDs.

(ID: SpS02) Acute Neurology


3:00:00 PM - 4:30:00 PM

Room Budapest

Chairpersons: Simon Jung, Bern, Switzerland (ID: 47914)

Pitfalls in the management of neurological emergencies (ID: SPS02_1)

Simon Jung, Bern, Switzerland (ID: 47914)

Pitfalls in the management of patients on the neuro ICU (ID: SPS02_2)

Robin Howard, London, United Kingdom (ID: ??)

Outcome prediction in patients with hypoxic encephalopathy (ID: SPS02_3)

Andrea Rossetti, Lausanne, Switzerland

(ID: SPS03) MDS European Basal Ganglia Club


3:00:00 PM - 4:30:00 PM

Room Lisbon

Chairpersons: Angelo Antonini, Padua, Italy (ID: 37557)

C. David Marsden Lecture: The impunity of the Basal Ganglia to interventional therapies in

Parkinson's disease - An advantageous mystery (ID: SPS03_1)

José Obeso, Madrid, Spain (ID: 24657)

Video Cases (ID: SPS03_2)

Carlo Colosimo, Italy

Cristian Falup-Pecurariu, Romania

(ID: SPS04) The care of Rare Neurological Diseases, 2020


4:45:00 PM - 6:15:00 PM

Room Budapest

Chairpersons: Antonio Federico, Siena, Italy

Marianne de Visser, Amsterdam, The Netherlands

Introduction: the need of care and the possibility to give it

Antonio Federico, Siena, Italy

New genetic therapies: for which diseases and for which patients?

Jean Marc Burgunder, Bern, Switzerland

Health or hope? The cost and availability of new orphan therapies in Europe.

Maria Judit Molar, Budapest, Hungary

Neurorehabilitation for Rare Diseases. From theory to practice

Dafin Muresanu, Romania

Conclusions

Marianne de Visser, Amsterdam, The Netherlands

Scientific Content:

The general care of rare neurologic diseases in Europe will be discussed, including its sustainability, the

cost-benefit ratio, the hope of the families, the scientific data on new gene therapies, and the

important role of neurorehabilitation. The audience will be provided with a global review on the

different care approaches to these often-neglected group of disorders, and one group of rare diseases

will be dealt with in-depth.

(ID: SPS05) New neurological guidelines

Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Main Auditorium

Chairpersons: Maurizio Leone, Italy

Marie Vidailhet

EAN guideline on the diagnosis of coma and other disorders of consciousness (ID: SPS05_1)

Daniel Kondziella (ID: )

EAN consensus for developing and reporting guidelines for rare neurological diseases(ID:

SPS05_2)

Katina Aleksovska

Monogenic cerebral small vessel diseases: diagnosis and therapy. Consensus

recommendations of EAN (ID: SPS05_3)

Hugh Markus

EAN guideline on the management of narcolepsy (update) (ID: SPS05_4)

Ulf Kallweit

Scientific Content:

This special session is the yearly appointment for presenting the most relevant guidelines produced by

EAN during the past year. EAN guidelines are currently suggested and prepared by ad-hoc Task Forces,

usually appointed by the Scientific Panels, according to a well-established procedure, requiring a first

proposal, and a protocol. Since 2019, 3 new guidelines were published in European Journal of

Neurology, 5 are submitted, 16 are ongoing, and 2 are at the protocol stage. Six further proposals have

been recently accepted. The EAN Guideline Production Group is in charge of controlling the guideline

production process and helping with methodological assistance, and has recently updated the

procedure, available in EANpages.

During the last two years concerns have been raised by the Task Forces, especially related the

methodology to be used in contexts lacking evidence, such as rare diseases. To enhance and improve

the development and reporting of guidelines for rare neurological diseases, EAN has appointed a task

force with the aim to produce a specific guidance through a Delphi consensus. The results of this expert

consensus will be presented in this session.

The other three guidelines are all dealing with disorders where evidence is lacking. A joint effort of the

Stroke and Neurogenetics Panels led to an expert consensus for the management of the most common

monogenic causes of juvenile stroke, including CADASIL, CARASIL, MELAS, and others. Recognition of

the genetic disorders causing stroke is important for a correct diagnosis, for genetic counselling and,

where available, for a correct therapeutic management.

A guideline on management of narcolepsy, a condition affecting approximately 1 out of 2000 persons

in Europe, has been produced by a task force of neurologists and sleep experts appointed by EAN in

agreement with the European Sleep Research Society and the European Narcolepsy Network.

Last, although acknowledging limited evidence to support diagnostic decisions in coma and other

disorders of consciousness, the EAN Panel Coma and Disorders of Consciousness has produced a

guideline to provide the state-of-the-art evidence in this field, summarizing data from bedside

examination techniques, functional neuroimaging and electroencephalography.

During this session, guideline papers on neurological management that were recently published in the

European Journal of Neurology by EAN and partner societies, will be introduced. If you wish to receive

more information on EAN guideline production, you are welcome to visit the EAN booth "Research".

(ID: SpS07) Resident and Research Fellow Section - Unleash your potential with EAN!

Sunday, 24 May 2020

4:45:00 PM - 6:15:00 PM

CbW Room

Chairpersons: Giovanni Di Liberto, Geneva, Switzerland (ID: 69196)

Successful stories from EAN Clinical Fellowship recipients (ID: SPS07_1)

Alberto Vogrig, Udine, Italy (ID: 44344)

Successful stories from EAN Research Fellowship recipients (ID: SPS07_2)

Bettina Balint, London, United Kingdom (ID: 49883)

TBA (ID: SPS07_3)

Ana Felipa De Freitas Ladeira, Lisbon, Portugal (ID 56648)

TBA (ID: SPS07_4)

Stefania Nannoni, Italy

Main aims:

1) Provide example of successful careers in Neurology boosted by EAN opportunities

2) Give the opportunity to RRFS member to ask questions to their colleagues who achieved

great results and managed to combine both clinical and research activities abroad.

3) Discuss the challenges that clinician-scientists have to face in the evolving landscape of

Neurology in Europe and how to bring back to their home countries the skills acquired.

4) Increase the awareness on the EAN fellowships as a successful career boosting scheme

For the 6th EAN congress, we are planning to organize a special session dedicated to the successful

stories of RRFS members who took advantage of EAN fellowships to unleash their potential and achieve

great results in the field of Neurology. The format of this special session is an interview in which

speakers will describe the impact of EAN fellowship in shaping their careers and then an open

discussion in which the participants can ask questions to the speakers. To promote this special session

as well as the call for EAN fellowships, the selected speakers will produce a small video of 3 min that

will serve as a trailer for both and will be uploaded on the EAN website.

(ID: SPS08) History of Neuroscience

Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Budapest

Chairpersons: Danielle Seilhean, Paris France

Gilles de la Tourette: how he defined Tourette Syndrome

Olivier Walusinski, France

History of neuropathology in Salpetriere : contribution from French and foreign neurologists Danielle Seilhean, Paris France

From Gall to Broca; localisation in neurology

Peter Köhler, Herleen, The Netherlands

(ID: SPS09) Relevance of SEX DIFFERENCES in neurological disorders

Monday, 25 May 2020

8:00:00 AM - 9:30:00 AM

Room Seville

Chairpersons: Maria Teresa Ferretti, Zurich, Switzerland (ID: 94868) Elena Moro, Grenoble, France (ID: 51361)

Sex differences and human brain: overview and update (ID: SPS09_1)

Maria Teresa Ferretti, Zurich, Switzerland (ID: 94868)

Sex differences in stroke (ID: SPS09_2)

Anne Hege Aamodt, Oslo, Norway (ID: 50157)

Sex differences in neurodegenerative disorders (ID: SPS09_3)

Gennarina Arabia, Cosenza, Italy (ID: 63466)


A mounting body of evidence indicates that the male and female brains are affected by and respond

differently to a variety of neurological diseases. Whether this is due to biological (sex) or

socioeconomic reasons (gender) is still debated. This symposium will provide an overview of the issue,

by first introducing the concept of sex (biological makeup) and gender (socioeconomic construct), and

then offering examples from key neurological disease areas in the field of neurology. The symposium

will cover clinical aspects related to risk factors, progression and response to treatment in Stroke,

Alzheimer’s disease, and Parkinson’s disease in men and women, with particular attention to hormonal

interactions. These differences are of great interest for designing trials, improving prediction,

prevention and treatment approaches of neurological diseases.

(ID: SpS10) EAN/AFAN: Stroke management – What Africa can tell us

Tuesday, 26 May 2020

8:30:00 AM - 10:00:00 AM

Room Berlin

Chairpersons: Erich Schmutzhard, Innsbruck, Austria (ID: 7155)

Jean-Michel Vallat, Limoges, France (ID: 6574)

Thrombolysis and thrombectomy in North Africa: Challenges and Moroccan experience (ID:

SPS10_1)

Faouzi Belahsen, Fès, Morocco (ID: 93727)

Adapting stroke guidelines to African needs (ID: SPS10_2)

José M. Ferro, Lisbon, Portugal (ID: 19435)

Rehabilitation in resource-poor settings: does it work in Africa? (ID: SPS10_3)

Foad Abd-Allah, Cairo, Egypt (ID: 96105)


Stroke is a major public health concern worldwide. In low-middle income countries, especially in Africa,

nowadays, the management of acute strokes is often poor for several evident reasons; so, the

application of evidence-based acute stroke care interventions for optimal patient outcomes in such

countries seems quite often but not everywhere, still inadequate. It appears that guidelines which are

recommended in the Western world have to be adapted to this context. In a few countries like in

Maghreb, Ghana, Nigeria, South Africa and a few others, scarce studies indicate emerging evidence of

the availability of stroke unit care in hospital settings. So, at this time it seems interesting to discuss

and share the various experiences of neurologists from the African continent who take care of stroke

patients at the acute stage. It also must be stressed that rehabilitation is always and everywhere very

useful to take in charge, as soon as possible, such patients in adapted structures.

(ID: SPS12) European Brain Council: Severe patients in neurology and psychiatry: Detecting

- Managing – Refining

Sunday, 24 May 2020

8:00:00 AM - 9:30:00 AM

Room Seville

Chairpersons: Joke Jaarsma, Treasurer, European Brain Council

Frédéric Destrebecq, Executive Director, European Brain Council

Introduction

Joke Jaarsma

The Perspective of Neurology David B. Vodusek

Similarities in Psychiatry

Philip Gorwood

An integrated approach for managing severe patients living with brain disorders

Bruno Dubois

Open discussion

Frédéric Destrebecq

Wrap-up

Joke Jaarsma

Scientific/Educational Content: A wide range of commonalities exist in the domains of neurology and psychiatry as regards to the management of patients living with severe neurological or mental conditions. Such diseases greatly impact the lives of those affected. The aim of this session is to look into developing appropriate solutions and strategies that benefit patients in neurology and psychiatry. For that purpose, the session will bring together different perspectives on common aspects and challenges related to diagnosis and management as well as refinement of treatments and long-term specialist care of severely affected patients in neurology and psychiatry.

symposium - ean.org...this symposium will address the most frequent causes of movement disorders...

Documents